Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00054431 · ClinicalTrials.gov registry record · Phase 2
Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia
A Phase 2 study of Accelerated Phase Chronic Myelogenous Leukemia and Chronic Myelogenous Leukemia, BCR-ABL1 Positive, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT00054431 is a Phase 2 study of Accelerated Phase Chronic Myelogenous Leukemia and Chronic Myelogenous Leukemia, BCR-ABL1 Positive that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 80 participants, below the 173-participant average among 11 other Accelerated Phase Chronic Myelogenous Leukemia trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00054431, a Phase 2 study of Accelerated Phase Chronic Myelogenous Leukemia and Chronic Myelogenous Leukemia, BCR-ABL1 Positive, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial is studying how well giving imatinib mesylate together with decitabine works in treating patients with accelerated or blast phase chronic myelogenous leukemia. Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving imatinib mesylate together with decitabine may kill more cancer cells
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG imatinib mesylate
- DRUG decitabine
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2003-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00054431
The ClinicalTrials.gov registry entry for NCT00054431 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 173-participant average among 11 other Accelerated Phase Chronic Myelogenous Leukemia trials with a reported enrollment target (54% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Accelerated Phase Chronic Myelogenous Leukemia appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00054431 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00054431 about?
NCT00054431 is a clinical study titled "Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia". This phase II trial is studying how well giving imatinib mesylate together with decitabine works in treating patients with accelerated or blast phase chronic myelogenous leukemia. Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Drugs us...
What is the current status of trial NCT00054431?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2003-01.
What conditions does trial NCT00054431 study?
This clinical trial studies the following conditions: Accelerated Phase Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blastic Phase Chronic Myelogenous Leukemia, Childhood Chronic Myelogenous Leukemia, Relapsing Chronic Myelogenous Leukemia.
What interventions are being tested in trial NCT00054431?
The interventions under investigation include: laboratory biomarker analysis (OTHER), imatinib mesylate (DRUG), decitabine (DRUG).
Who is sponsoring clinical trial NCT00054431?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00054431 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Accelerated Phase Chronic Myelogenous Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies
COMPLETED · Phase 2
-
Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
COMPLETED · Phase 2
-
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
COMPLETED · Phase 2
-
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
COMPLETED · Phase 2
-
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
ACTIVE NOT RECRUITING
-
Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Accelerated Phase Chronic Myelogenous Leukemia
All registered trials for this condition
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.